CannBioRx Life Sciences Corp - Asset Resilience Ratio
CannBioRx Life Sciences Corp (ATNFW) has an Asset Resilience Ratio of 93.46% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ATNFW working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2019)
This chart shows how CannBioRx Life Sciences Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ATNFW total asset value.
Liquid Assets Composition Over Time
This chart breaks down CannBioRx Life Sciences Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CannBioRx Life Sciences Corp balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.30 Billion | 93.46% |
| Total Liquid Assets | $10.30 Billion | 93.46% |
Asset Resilience Insights
- Very High Liquidity: CannBioRx Life Sciences Corp maintains exceptional liquid asset reserves at 93.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CannBioRx Life Sciences Corp Industry Peers by Asset Resilience Ratio
Compare CannBioRx Life Sciences Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for CannBioRx Life Sciences Corp (2017–2019)
The table below shows the annual Asset Resilience Ratio data for CannBioRx Life Sciences Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 22.89% | $11.88 Million | $51.88 Million | -76.88pp |
| 2018-12-31 | 99.77% | $118.17 Million | $118.44 Million | +0.17pp |
| 2017-12-31 | 99.60% | $116.59 Million | $117.06 Million | -- |
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more